ENB Therapeutics
- | Biotech or pharma, therapeutic R&D
ENB Therapeutics is a clinical stage company developing First-in-Class selective ETBR inhibitors that drive immunotherapy efficacy in patients that are refractory to anti-PD1 and standard of care therapies. Our lead product ENB-003 demonstrates single agent activity and is well tolerated, demonstrating no DLTs in combination with pembrolizumab in a completed Phase 1 study.
Address
New YorkNY
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}